Full-Time

Principal Engineer

Early Innovation R&D

Posted on 8/18/2026

Deadline 8/25/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$117k - $201.3k/yr

+ Annual performance bonus

Raritan, NJ, USA

In Person

Up to 20% travel may be required.

Bachelor's

Category
Software Engineering (1)
Required Skills
Six Sigma
Machine Learning
Quality Assurance (QA)
Risk Management

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A minimum of a bachelor's degree in systems engineering, electrical engineering, mechanical engineering, electromechanical engineering, robotics, biomedical engineering, or a related technical discipline is required.
  • A minimum of 8 years of progressive experience in medical device research and development, systems engineering, electromechanical product development, connected devices, digital health, software-enabled products, advanced engineering, external innovation, or related technical roles is required.
  • Experience leading front-end innovation activities, including customer discovery, unmet need definition, concept development, architecture definition, feasibility testing, prototype development, technical de-risking, and transition to development programs is required.
  • Experience evaluating external technologies and partners, conducting technical due diligence, and making evidence-based recommendations is required.
  • Working knowledge of medical device design controls, systems engineering, risk management, verification and validation, requirements management, quality systems, and regulated product development is required.
  • Demonstrated ability to communicate complex technical, clinical, and business information clearly to senior leaders, clinicians, technical teams, and external partners is required.
Responsibilities
  • Identify, assess, and recommend external technologies, platforms, and partnership opportunities aligned to the MedTech Surgery Wound Closure & Healing strategy and innovation pipeline.
  • Conduct technical due diligence on startups, academic innovations, licensing opportunities, and strategic collaborations, including evaluation of clinical need, technical feasibility, intellectual property, regulatory pathway, quality considerations, scalability, and strategic fit.
  • Develop technology landscapes, target scans, competitive intelligence, and evidence summaries across surgical, wound closure, engineered systems, electromechanical, connected device, automation, sensing, software, and digital solution spaces.
  • Translate customer, clinical, workflow, and technology insights into problem statements, user needs, system requirements, subsystem requirements, architecture considerations, risk profiles, and evidence-based recommendations.
  • Engage clinicians, key opinion leaders, academic collaborators, suppliers, incubators, accelerators, and external innovation partners to maintain an innovation pipeline.
  • Lead front-end innovation activities, including customer discovery, unmet need definition, opportunity framing, concept generation, system architecture exploration, feasibility planning, prototype evaluation, integration testing, and proof-of-concept execution.
  • Partner cross-functionally to advance opportunities from assessment through technology de-risking, system integration, prototype builds, verification strategy, and transition to formal product development, as appropriate.
  • Prepare and communicate technical assessments, business cases, risk profiles, and recommendations to senior leaders and governance forums to support portfolio prioritization and investment decisions.
  • Follow applicable laws and regulations, company policies and procedures, design control expectations, quality system requirements, and health, safety, and environmental practices.
Desired Qualifications
  • An advanced degree in systems engineering, electrical engineering, mechanical engineering, electromechanical engineering, robotics, biomedical engineering, or a related technical discipline is preferred.
  • Experience with engineered medical systems, electromechanical platforms, connected medical devices, sensors, actuation, automation, software-driven products, data platforms, artificial intelligence and machine-learning-enabled solutions, digital health technologies, or clinical decision support tools is preferred.
  • Experience integrating hardware, software, sensing, data, user interface, and disposable or device components into regulated medical device systems is preferred.
  • Prior experience in strategic partnerships or external innovation is preferred.
  • Experience with Design Excellence, Six Sigma, TRIZ, Design Thinking, Stanford Biodesign, or another structured innovation and problem-solving methodology.
  • An active network within medical device engineering, digital health, connected device, software, automation, robotics, health technology, or relevant startup ecosystems.
  • Coaching, critical thinking, innovation, Model-Based Systems Engineering, organizing, project management, report writing, requirements analysis, research and development, researching, SAP Product Lifecycle Management, scripting languages, software acquisitions, software development management, software engineering practices, software quality assurance, systems development lifecycle, technological proficiency, and training people.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.